GERM CELL TUMOR
Clinical trials for GERM CELL TUMOR explained in plain language.
Never miss a new study
Get alerted when new GERM CELL TUMOR trials appear
Sign up with your email to follow new studies for GERM CELL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells injected directly into brain show promise for kids with deadly tumors
Disease control OngoingThis early-phase study tests whether specially engineered immune cells (CAR T cells) can be safely given directly into the brain or spinal fluid of children and young adults with HER2-positive brain tumors that have come back or not responded to standard treatments. The therapy a…
Matched conditions: GERM CELL TUMOR
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 16, 2026 22:21 UTC
-
Proton beam therapy aims to shrink brain tumors with fewer side effects
Disease control OngoingThis study looks at whether proton beam radiation can safely treat germ cell tumors in the brain and spine while causing fewer side effects than standard photon radiation. About 45 participants aged 3 to 25 will receive proton radiation and be monitored for side effects and tumor…
Matched conditions: GERM CELL TUMOR
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 16, 2026 22:20 UTC
-
New hope for incurable cancer: drug shows promise in resistant tumors
Disease control OngoingThis study tests the drug cabozantinib in 50 adults with germ cell tumors that have not responded to standard chemotherapy. The goal is to see if the drug can shrink tumors or stop them from growing for at least three months. Participants will take the drug until their disease wo…
Matched conditions: GERM CELL TUMOR
Phase: PHASE2 • Sponsor: Jennifer King • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New drug duo targets stubborn germ cell cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, in people whose germ cell tumors have come back or not responded to standard treatment. The goal is to see if this combination can shrink tumors or control the disease. About 30 adults with measurable tumors w…
Matched conditions: GERM CELL TUMOR
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Engineered immune cells take aim at childhood cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…
Matched conditions: GERM CELL TUMOR
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
Engineered immune cells take on tough childhood cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for children and young adults (ages 1–30) with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells carrying…
Matched conditions: GERM CELL TUMOR
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
Rare ovarian cancer survivors: what happens years after treatment?
Knowledge-focused OngoingThis study looks at women who had rare ovarian cancers and are now in remission for at least two years. Researchers want to understand how chemotherapy affects their energy, heart, lungs, and overall quality of life. Participants fill out questionnaires and may have medical tests…
Matched conditions: GERM CELL TUMOR
Phase: NA • Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:09 UTC
-
Blood marker may predict cancer return in testicular cancer patients
Knowledge-focused OngoingThis study is testing whether a blood marker called miRNA 371 can predict if germ cell tumors (a type of cancer) will return after treatment. Researchers are collecting blood samples from 956 patients with newly diagnosed germ cell tumors and tracking their outcomes. The goal is …
Matched conditions: GERM CELL TUMOR
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC